BusinessPhoto: Mint MarketsJM Financial Gives Buy Call on Symbiotec Pharmalab with 27% Upside
JM Financial initiated coverage of Symbiotec Pharmalab with a Buy rating and set a target price of ₹1,622, indicating a potential 27% upside. The firm expects growth driven by new capacity, CDMO services, and complex injectables to boost revenue, EBITDA, and profit through fiscal year 2029.
Mint Markets·

